Literature DB >> 28763372

Xinxuekang Regulates Reverse Cholesterol Transport by Improving High-density Lipoprotein Synthesis, Maturation, and Catabolism.

Guang-Xin Dong1, Wen-Wen Li, Ruo-Zhu Wang, Wen-Jun Zou, Zhen-Dong Zhong, Bo-Gang Li.   

Abstract

Di'ao Xinxuekang (XXK) is an herbal product in China and the Netherlands that has been clinically shown to attenuate atherosclerosis; however, the underlying antiatherosclerotic mechanism remains unclear. Because of its role in cholesterol homeostasis, reverse cholesterol transport (RCT) is a potential target for these beneficial effects. This study investigated the effects of XXK on RCT and related proteins. After treating ApoE-deficient mice with XXK for 8 weeks, we observed an increase in the expression level of ATP-binding cassette transporter A1 and ATP-binding cassette transporter G1, which in turn stimulated cholesterol efflux and reduced aortic atherosclerotic lesion area. XXK also increased high-density lipoprotein (HDL) synthesis by modulating the peroxisome proliferator-activated receptor γ/liver X receptor α/ATP-binding cassette transporter A1 pathway and promoted HDL maturity by increasing serum lecithin-cholesterol acyltransferase. In addition, XXK improved the selective uptake of HDL-cholesteryl ester by increasing the expression of scavenger receptor class B type I. This is the first study to show that XXK confers a regulation of RCT, at least in part, by improving HDL synthesis, maturation, and catabolism.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28763372     DOI: 10.1097/FJC.0000000000000500

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway.

Authors:  Jiyi Liang; Wei Li; Honglin Liu; Xiaofen Li; Chuqiao Yuan; Wenjun Zou; Liping Qu
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

Review 2.  Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review.

Authors:  Shiqi Chen; Xiaoxiao Wu; Tong Li; Yang Li; Baofu Wang; Weiting Cheng; Yu Teng; Jingjing Yang; Hui Meng; Lei Wang; Ziwen Lu; Yangyang Jiang; Yahong Wang; Mingjing Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-27       Impact factor: 2.629

Review 3.  The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines.

Authors:  Li Lu; Xiaodong Sun; Yating Qin; Xiaomei Guo
Journal:  Biomed Res Int       Date:  2018-06-13       Impact factor: 3.411

4.  Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9.

Authors:  Liping Qu; Didi Li; Xiaoping Gao; Yongwei Li; Jianming Wu; Wenjun Zou
Journal:  Front Pharmacol       Date:  2018-11-01       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.